NCT06178445View on ClinicalTrials.gov

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

April 30, 2028

Conditions
Biliary Tract CancerHER2 Gene MutationHER2
Interventions
DRUG

SOC plus trastuzumab and pembrolizumab

SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab

Trial Locations (7)

Unknown

RECRUITING

Charité Universitätsmedizin, Berlin

NOT_YET_RECRUITING

Krankenhaus Nordwest (KHNW), Frankfurt

RECRUITING

Universitätsklinikum Freiburg, Freiburg im Breisgau

RECRUITING

Universitätsklinikum Göttingen, Göttingen

RECRUITING

Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg

RECRUITING

Medizinische Hochschule Hannover, Hanover

RECRUITING

LMU München, München

All Listed Sponsors
collaborator

Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel

UNKNOWN

collaborator

MSD Sharp & Dohme GmbH, Germany

UNKNOWN

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER